{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:41:39Z","timestamp":1784076099404,"version":"3.55.0"},"reference-count":0,"publisher":"National Library of Serbia","issue":"12","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministry of Education, Science and Technological Development of the Republic of Serbia","doi-asserted-by":"publisher","award":["175090"],"award-info":[{"award-number":["175090"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["VSP","VOJNOSANIT PREGL","VOJNOSANITETSKI PREG"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>Background\/Aim. Botulinum toxin (BTX) irreversibly inhibits presynaptic\n   acetylcholine release with subsequent relaxation of abnormally contracting\n   muscles. It is an effective and well tolerated treatment with long-term\n   benefit in a variety of movement disorders and other neurological and\n   non-neurological disturbances. The aim of our study was to present our\n   experience with BTX type A in treatment of different forms of focal\n   dystonias. ?ethods. ? hundred of patients with different focal dystonias\n   (spastic torticollis, blepharospasm and graphospasm) from the Botulinum Toxin\n   Outpatients Department, Clinic for Neurology, Clinical Center of Serbia, were\n   included in the study. All the patients were examined and rated at baseline\n   visit prior to BTX application and on the following visit, after 3-4 months,\n   using self-assessment improvement questionnaire and standardized rating\n   scales. Results. The improvement of ? 50% was presented in 68.2% of all (199)\n   the analyzed applications. Independent predictors of good response to the\n   therapy (improvement ? 50%) were male sex (p = 0.011), the presence of\n   sensory trick (p = 0.013) and the total number of BTX applications (p =\n   0.002). The patients with spastic torticollis and blepharospasm showed a\n   statistically significantly better BTX effect (improvement 57.3 ? 27.5% and\n   54.1 ? 28.3%), respectively than the graphospasm group (26.7 ? 25.6%). Most\n   of the patients did not have therapy complications (81.4% and 72% in two\n   applications). Side effects in the remaining patients (muscle weakness,\n   dysphagia, ptosis, double vision, neck weakness and lacrimal dysfunction)\n   lasted for 28.3 ? 18.6 days after the first treatment and 32.5 ? 36.2 days\n   after the second one. Conclusion. BTX is safe and highly effective in\n   long-term treatment of patients with different forms of focal dystonia, with\n   only mild and well-tolerated side-effects.<\/jats:p>","DOI":"10.2298\/vsp131224114t","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T15:09:20Z","timestamp":1446217760000},"page":"1069-1073","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department"],"prefix":"10.2298","volume":"72","author":[{"given":"Aleksandra","family":"Tomic","sequence":"first","affiliation":[{"name":"Clinical Center of Serbia, Clinic for Neurology, Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-7284","authenticated-orcid":false,"given":"Balsa","family":"Vujovic","sequence":"additional","affiliation":[{"name":"Clinical Center of Montenegro, Clinic for Neurology, Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-4865","authenticated-orcid":false,"given":"Marina","family":"Svetel","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia, Clinic for Neurology, Belgrade + Faculty of Medicine, Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Dragasevic-Miskovic","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia, Clinic for Neurology, Belgrade + Faculty of Medicine, Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Petrovic","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia, Clinic for Neurology, Belgrade + Faculty of Medicine, Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Pekmezovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Epidemiology, Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"S.","given":"Vladimir","family":"Kostic","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia, Clinic for Neurology, Belgrade + Faculty of Medicine, Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1078","container-title":["Vojnosanitetski pregled","Military Medical and Pharmaceutical Journal of Serbia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T11:15:41Z","timestamp":1685358941000},"score":1,"resource":{"primary":{"URL":"https:\/\/doiserbia.nb.rs\/Article.aspx?ID=0042-84501500114T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2298\/vsp131224114t","relation":{},"ISSN":["0042-8450","2406-0720"],"issn-type":[{"value":"0042-8450","type":"print"},{"value":"2406-0720","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}